C-PQV4X-tosis
mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PQV4
C-PQV4C-PQV4mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
New in Nature Portfolio on microglial regulation in Alzheimer’s disease. | Ruslan Rust LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s
Breakthrough in Mitochondrial Biology for Parkinson's Disease | Yotam Nisemblat posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … -tosis 459 followers 4d We are excited to share that X-tosis has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to advance our novel mitochondrial-based therapy for Parkinson’s disease. We greatly appreciate the MJFF’s support, which accelerates the development of XTS001 and brings us closer to a first-in-class treatment that targets the underlying biology of the disease. https://www.x-tosis.com/a2 #ParkinsonsDisease #Biotech #DrugDevelopment … otech #DrugDevelopment #Mitochondria #Neuroscience #Innovation X-tosis Receives Grant from The Michael | X Tosis x-tosis.com 12 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Desmond Owusu Kwarteng 2w Edited Report this post Our new preprint explores how ApoE, lipids and amyloid beta interact within plaques in Alzheimer’s disease. Most studies on ApoE-amyloid interactions rely on simplified, neutral-lipid model systems. Inste
X-TOSIS INC - Government Contracts & Awards | CLEATUS Skip to main content Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings! Live CLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, July 8 at 2:00 PM EDT Register Free → Get CLEATUS Free Trial Features How It Works Resources Pricing Case Studies Get CLEATUS Free Trial Log in Government Contracts Agencies Officers Contractors NAICS Vehicles Search Top Government / Contractors / X-TOSIS INC X-TOSIS INC UEI: DEYECCHW3JB8 CAGE: 0NQ46 X-TOSIS INC is a federal contr … 325412 325412 (Primary) Overview Awarded Contracts Federal Contracting Overview Award totals, agency breakdown, NAICS distribution, and geographic footprint. AI Capability Profile X-TOSIS INC specializes in chemical manufacturing processes aligned with NAICS 325412, focusing on the production of industrial organic chemicals and specialty formulations for government and defense applications. The company’s technical expertise centers on precision synthesis, process scale-up, an … al programs. No agency relationships can be inferred from available data, as no award history is recorded. Consequently, there is no evidence of consistent engagement with specific federal departments or mission areas. The company’s primary industry focus is industrial chemical manufacturing, which in practice involves the formulation and production of reagents, intermediates, and specialty compounds used in defense, environmental remediation, or laboratory applications. Thei … emini [email protected] Contact Us Features AI GovCon Agent Smart Contract Matching Proposal Writer Pursuit Management AI Document Hub Market Intelligence AI Workflows Company Product Pricing Compare GovCon Software Integrations Security Product Updates Learn Blog How CLEATUS Works FAQs Schedule a Demo Webinars Customers Case Studies Testimonials Implementation Plan Help Center CLEATUS Community Tools & Data Free Tools All Free Tools AI FAR Navigator Capability Statement Buil
X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy - FinanceWire - Financial Press Release Distribution, Finance PR Toggle navigation Homepage Newsroom Pricing Blog About Us FAQs Contact Log in X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy Posted by FinanceWire on June 23, 2026 | Featured Gainesville, United States, June 23rd, 2026, FinanceWire X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson’s Disease Therapy. The … neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Parkinson’s Disease Therapeutics Pipeline Program. The funding will support advancement of XTS001, the lead candidate from the company’s MitoXTS platform, a patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, toward clinical development for the treatment of Pa … toward clinical development for the treatment of Parkinson’s disease (PD). The grant was awarded following a competitive peer-review process evaluating scientific innovation and translational potential. The MJFF Parkinson’s Disease Therapeutics Pipeline Program accelerates promising PD therapies from preclinical to clinical stages by supporting innovative approaches that address core disease mechanisms. XTS001 is a brain-penetrant, orally available small molecule designed to … ial function and prevention of apoptosis triggered by cellular stressors. “This grant from MJFF is a major milestone for X-tosis and represents a strong validation of our MitoXTS approach to addressing unmet needs in Parkinson’s and other neurodegenerative diseases,” said Yotam Nisemblat, Chief Scientific Officer of X-tosis and Principal Investigator on the project. “By preserving mitochondrial integrity upstream in the neurodegeneration cascade, we aim to shift treatment fro … ance confirmatory studies, biomarker development, and IND-enabling work.” “This award from The Michael J. Fox Foundation is more than funding; it is support for further investigation of our scientific approach that mitochondrial dysfunction is a central addressable driver of Parkinson’s disease,” said Erin Henderson, CEO of X-tosis , Inc. “We bel
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account June 23, 2026 09:43 ET | Source: X-tosis X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward... January 08, 2025 12:57 ET | Source: X-tosis X-tosis to Present
X-tosis: Leading the charge on Alzheimer's with mitochondrial therapy | Offer Shina posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
General 1 — Alchem Laboratories Corporation 0 Skip to Content Home Team Capabilities Overview Synthesis Discovery Manufacturing Analytical Clinical APIs Partners Contracts Contact Open Menu Close Menu Home Team Capabilities Overview Synthesis Discovery Manufacturing Analytical Clinical APIs Partners Contracts Contact Open Menu Close Menu Home Team Folder: Capabilities Back Overview Synthesis Discovery Manufacturing Analytical Clinical APIs Partners Contracts Contact DEDICATED TO EXCELLENCE IN CUSTOM SYNTHESIS Alchem can be a value-creating partner for both established and start-up pharma
X-tosis Receives Grant from The Michael J. Fox Foundation --> Accessibility: Skip TopNav X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy June 23, 2026 09:43 ET | Source: X-tosis X-tosis GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward supports advancement of X-tosis’s mitochondrial approach and accelerates development of its lead Parkinson’s candidate toward the clinic. X-tosis, Inc. , a preci … neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) through its Parkinson's Disease Therapeutics Pipeline Program. The funding will support advancement of XTS001, the lead candidate from the company's MitoXTS platform, a patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, toward clinical development for the treatment of Pa … toward clinical development for the treatment of Parkinson's disease (PD). The grant was awarded following a competitive peer-review process evaluating scientific innovation and translational potential. The MJFF Parkinson's Disease Therapeutics Pipeline Program accelerates promising PD therapies from preclinical to clinical stages by supporting innovative approaches that address core disease mechanisms. XTS001 is a brain-penetrant, orally available small molecule designed to … ial function and prevention of apoptosis triggered by cellular stressors. “This grant from MJFF is a major milestone for X-tosis and represents a strong validation of our MitoXTS approach to addressing unmet needs in Parkinson's and other neurodegenerative diseases,” said Yotam Nisemblat, Chief Scientific Officer of X-tosis and Principal Investigator on the project. “By preserving mitochondrial integrity upstream in the neurodegeneration cascade, we aim to shift treatment fro … vance confirmatory studies, biomarker development, and IND-enabling work.”“This award from The Michael J. Fox Foundation is more than funding; it is support for further investigation of our scientific approach that mitochondrial dysfunction is a central addressable driver of Parkinson’s disease,” said Erin Henderson, CEO of X-tosis , Inc. “We bel
X-tosis Email Formats Login Get Started X-tosis Email Formats Biotechnology Research • • 1-10 Employees Get Verified Emails Of X-tosis Employees X-tosis Email Formats X-tosis uses 2 email format s . The most common is {first initial} (e.g., [email protected] ), used 60 % of the time. Format Example Percentage {first initial} [email protected] 60 % {first name} [email protected] 40 % Get Verified Emails Key Contact at X-tosis Erin Henderson Co-Founder and Chief Executive Officer @x-tosis.com View Details View All Employees Overview About Employees Insights Funding Trending Companies FAQ Company overview
X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy | The Manila Times --> --> Sunday, June 28, 2026 Today's Paper X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOT … TMT 127TH ANNIVERSARY QUIZZES GAMES TMT Newswire GlobeNewswire X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy By GlobeNewswire June 23, 2026 10 Resize Small Medium Large GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward supports advancement of X-tosis’s mitochondrial approach a … neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) through its Parkinson's Disease Therapeutics Pipeline Program. The funding will support advancement of XTS001, the lead candidate from the company's MitoXTS platform, a patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, toward clinical development for the … rd clinical development for the treatment of Parkinson's disease (PD). The grant was awarded following a competitive peer-review process evaluating scientific innovation and translational potential. Get the latest news delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy . The MJFF Parkinson's Disease Therapeutics Pipeline Program acce … ial function and prevention of apoptosis triggered by cellular stressors. "This grant from MJFF is a major milestone for X-tosis and represents a strong validation of our MitoXTS approach to addressing unmet needs in Parkinson's and other neurodegenerative diseases,” said Yotam Nisemblat, Chief Scientific Officer of X-tosis and Principal Inv
--> Our Team | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Our Team At X-tosis, we’re a cross-functional team of scientists, operators, and advisors advancing therapies that target mitochondrial dysfunction in neurodegenerative disease. Erin Henderson CEO, President & Co-Founder Board Board Naz Bashir, Ph.D. Board Chair Board Yotam Nismblat, M.Sc. CSO & Co-Founder Management Board Ofer Shina COO & Co-Founder Management Board Josh Pan, Ph.D. Chief of Staff, Hea
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram Instagram Log In Sign Up Close Never miss a post from ufinnovate Sign up for Instagram to stay in the loop. Sign up Log in ufinnovate and ps27.ventures More options ufinnovate 144w Whatever you need, it’s at the #CIED ! 💡 On this week’s #TechTuesday , Laurence Andrews and Melanie Moron are at Blount Center, one of @santafecollege ’s newest buildings to talk about their incubator, CIED. They target just about anybody, helping start and grow their business. 🌱 One of their upcoming events, the Veterans Founders Forum, will take place on November 2nd in collaboration with @ps27.venture
Instagram Instagram Log In Sign Up Close Never miss a post from auxilium_worcester Sign up for Instagram to stay in the loop. Sign up Log in auxilium_worcester • Follow More options auxilium_worcester 29w “We have touched it all here- legal, insurance, sales, marketing, pitch decks… the network has been incredible.” Tom Schofield, Founder of Splice Histology Inc, reflects on his participation in Auxilium’s first Accelerator cohort and highlights the breadth of support he received throughout the program. From funding and mentorship to a strong community of peers, Tom experienced what it means t … businesses and navigate every stage of their journey. Explore our programs and apply today {Link In Bio} Load more comments makinitmarketing Verified 29w We love working with Tom on his marketing 👏 it’s been so cool learning all the ins & outs of what Splice offers to their customers. 1 like Reply Like 14 Comment 1 Share Save December 3, 2025 Log in to like or comment. More posts from auxilium_worcester Carousel Carousel Carousel Clip Clip See more posts Meta About Blog
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> X-Tosis | Innovative Alzheimer's Disease Treatments & Drug Development top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Saving Brain Cells. Changing Lives. X-tosis is a precision-medicine platform company developing first-in-class mitochondrial therapeutics to prevent neuronal loss. Transforming Neurodegenerative Disease Treatment with XTS Compounds X-tosis is advancing first-in-class mitochondrial therapeutics that target the root causes of neurodegeneration. Our VDAC1-modulating compounds are designed to restore mitochondria
X-tosis to Present at Seed Showcase 2025 Alongside the J.P. --> Accessibility: Skip TopNav X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics January 08, 2025 12:57 ET | Source: X-tosis X-tosis GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis , Inc., a pre-clinical biotech company transforming the treatment of neurodegenerative and mitochondrial dysfunction-related diseases, today announced that it has been selected to particip … e Recommended Reading June 23, 2026 09:43 ET | Source: X-tosis X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward... Read More
Instagram Instagram Log In Sign Up Close Never miss a post from ufinnovate Sign up for Instagram to stay in the loop. Sign up Log in ufinnovate • Follow More options ufinnovate 41w 🚀 Welcome to #RealElevatorPitches ! 🚀 This month, Jackson Streeter MD, director of UF Innovate | Ventures, visits the The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology and meets Dr. Courtney A. Miller. Dr. Miller is the co-founder of the @uflorida startup Myosin Therapeutics Inc. Myosin Therapeutics is tackling a whole new class of proteins in the body called molecular nanomotors
COMMUNIQUÉS West-GlobeNewswire | Page 3 | santé log --> Jump to navigation Recherche Rechercher E-revue SAD L'app Thémas Aidants Nutrition Espace pro Diabète Cicatrisation Infirmier Médecin Incontinence Allergies Addictions Dermato Cancer Fibromyalgie Diagnostic Microbiote Gynéco Obésité Neuro Sommeil Pediatrie Mon compte Display menu santé log La communauté des professionnels de santé Actualités Dossiers Abonnement Réseaux de santé BLOG Nasdaq Mon compte Abonnement S'abonner à la revue soin à domicile Actus Dossiers Réseaux E-revue SAD Théma Aidants Nutrition Espace pro Diabète Cica … focused on developing best-in- [...] Hennick Humber Hospital Receives Milestone Grant from the Canadian Institutes of Health Research 26/06/2026 TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- The Research Team at Hennick Humber Hospital (HHH) has been awarded a major research grant from the Canadian Institutes of Health Research (CIHR) as part of a $10 million [...] New Autism Research to be Presented at European Purine Scientific Meeting 26/06/2026 CALGARY, Alberta, June 26, 202 … lexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...] Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026 25/06/2026 NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des [...] NRx Pharmaceuticals Re
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> Copy of Our Team | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Our Team At X-tosis, we’re a cross-functional team of scientists, operators, and advisors advancing therapies that target mitochondrial dysfunction in neurodegenerative disease. Erin Henderson CEO & President Naz Bashir, Ph.D. Board Chair Yotam Nismblat, M.Sc. CSO Ofer Shina COO Josh Pan, Ph.D. Chief of Staff & Head of BD Varda Shoshan-Barmatz, Ph.D. Inventor & SAB Andrew Skibo SAB Chair John Abernethy, M.D. SAB Matt LaVoie, Ph.D. S … and renewable technologies. Earlier in his career, he managed a university seed fund, achieving technology out-licensing, exits, and an IPO. Today, he is Co-Founder of an Omega-3 company, a Director at Evolutia Venture Partners, and serves on advisory boards and committees including Leela Capital and the Vector Innovation Fund. In addition to his commercial ventures, Naz contributes as a trustee of World Science Aid, supporting science as a tool for global fairness and safety … n-Barmatz has been recognized with numerous honors, including the Teva Founders Award for pioneering cancer research, the Ben-Gurion Award for her scientific leadership, and election as a Fellow of the International Union of Physiological Sciences Academy. In 2024, the journal Biomolecules dedicated a special issue to her career, acknowledging her central role in advancing mitochondrial science. As Head of the X-tosis Scientific Advisory Board, she brings unmatched expertise … l practice readiness. With experience leading curriculum design, mentoring, and residency programs, she contributes valuable expertise in clinical pharmacy and education that strengthens the translational and clinical impact of X-tosis’s research efforts. John H. Abernethy, M.D Dr. John H. Abernethy is a physician and clinical leader with over 20 years of experience in family medicine, addiction medicine, and translational research. Board certified in both family and ad
JPM Presentation Tracker – RESI Conference Skip to content Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program Guides Photo Albums Registration RESI San Diego (June) RESI Boston (Sept) Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs … ic Fibrosis Foundation 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd Funding, Family Offices, and Foundations RedCrow 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd Funding, Family Offices, and Foundations Venable LLP 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd F
India's CAR-T Therapy Revolution: Affordable Cancer Care for 100,000 Patients | Immuneel Therapeutics Pvt. Ltd. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By c … perienced mentors, and a strong network of industry and startup connections. 👉 Apply here: https://lnkd.in/emyZ8y_7 #AccelerationThroughAccess #startups #innovation #entrepreneurs 30 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 71,670 followers View Profile Follow Explore related topics Advancing caT Cell Therapies for Cancer Treatment Innovations Improving Car T Treatments T-Cell Transfer Therapy for Cancer Treatment Advancements i
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Gen XY Updates from GlobeNewswire | The Active Age Menu Health x Wellness The Gen XY Lifestyle Insights + interviews Gen XY News Gen XY Updates Health x Wellness The Gen XY Lifestyle Insights + interviews Gen XY News Gen XY Updates Gen XY Updates from GlobeNewswire Tweet Pin It TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation 2026-06-27T16:42:53Z New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety co … KMEZ® (ATI-1501) commercial momentum building in U.S. marketUS$40 million NIAID award supporting VXV-01 advancement through Phase 1 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance 2026-06-26T21:15:00Z BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice ( … Naturals, the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient... VitalHub Announces Results of Annual General Meeting of Shareholders 2026-06-26T20:30:00Z TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the voting results from its annual general meeting of shareholders held virtually on... Crescent Biopharma Announces Grants … Execution and Shareholder Value Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma 2026-06-26T17:20:00Z SAN FRANCISCO, June 26, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the... Johnson & … sory Committee meeting scheduled for July 29, 2026––Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– New Yorkers Celebrate Independence Through Helen Keller's Legacy at Premiere of Groundbreaking Documentary Possibilities 2026-06-26T13:50:17Z Blind artists, educators, advocates, and creatives
Neurodegenerative disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Neurodegenerative disease Neuroscience Lilly bets up to $800M for BioArctic’s brain delivery tech Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. The pharma hasn’t specified which neurodegenerative disease it will target. June 22, 2026 · 2 min read ·& … apy June 24, 2026 · 4 min read Press Releases X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy June 23, 2026 · 4 min read Press Releases TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio June 23, 2026 · 1 min read Can-Fite Publishes Peer-Reviewed Scientific … min read Press Releases Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients June 17, 2026 · 3 min read Press Releases Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease June 16, 2026 · 8 min read Press Releases Coya Therapeutics to Host Virtual W … 2026 · 2 min read Press Releases AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease June 11, 2026 · 5 min read Press Releases Crownlands Releases Largest Open-Source Dataset of Living Patient Cells to Advance AI-Driven Research in Alzheimer’s and Neuroscienc
--> Technology | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Innovating Mitochondrial Protection Against Neurodegeneration Advancing Disease-Modifying Mitochondrial Medicine X-tosis is developing first-in-class therapeutics that address the upstream biology driving neurodegenerative diseases. Our approach centers on restoring mitochondrial stability and preventing neuronal death—an essential step toward true disease modification in conditions such as Alzheimer’s, Parkinson’s, ALS, and other disorders mar … undamental point of failure, XTS compounds hold potential for broad therapeutic application across diseases characterized by neuronal stress, metabolic imbalance, and inflammation. How XTS001 Works XTS001 targets the root cause of mitochondrial collapse by preventing VDAC1 oligomerization. In neurodegenerative disease: VDAC1 becomes overexpressed VDAC1 oligomerizes, forming toxic pores Mitochondria lose membrane potential and energy production Apoptotic factors leak into
--> About Us | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. We envision a world free of neurodegenerative diseases. X-tosis is dedicated to revolutionizing the treatment of neurodegenerative diseases, starting with Alzheimer’s and extending to other conditions. Our mission is to develop innovative solutions that target the underlying causes, offering hope to patients and their families. About Us X-tosis, founded in 2024, is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutic
Erin Henderson pitches X-tosis for neurodegenerative disease therapies | UF Innovate | Ventures posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … otentially restore sight by rejuvenating optic nerve cells, with aspirations to apply this technology to other organs like the liver and brain. • Despite the potential for cellular reprogramming to reverse aging, early research in mice showed the formation of cancerous cells, and the company's co-founder has a history of overhyping longevity treatments, indicating this field still faces considerable challenges and long-term development. #aging #longevity #medicine #clinicaltr
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram Instagram Log In Sign Up Close Never miss a post from thedollarstory Sign up for Instagram to stay in the loop. Sign up Log in thedollarstory • Follow More options thedollarstory 30w Funding news: Aspen Neuroscience, a clinical-stage biotechnology company, has closed a $115 million Series C financing round to advance its autologous regenerative therapies, particularly for Parkinson’s disease. Aspen Neuroscience is pioneering personalized cell replacement therapy by converting a patient’s own skin cells into new, dopamine-producing neurons, which are then transplanted into the brain.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Neuroscience - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Neuroscience Neuropsychiatric disorders Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space. June 26, 2026 · 2 min read · Tristan Man … re’s Phase 1/2 trial are sufficient to support an accelerated biologics license application. June 17, 2026 · 4 min read · Heather McKenzie Depression Alto’s depression candidate bolstered by independent study showing mood benefits Alto Neuroscience is advancing a depression drug based on the dopamine agonist pramipexole, which an independent study has found to help boost feelings of pleasure in patients with mood disorders. June 16, 2026 &nbs … LS) June 23, 2026 · 2 min read Press Releases X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy June 23, 2026 · 4 min read Press Releases Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 June 23, 2026 · 5 min read Press Releases BioMed X Launches Global Call for Research Proposals in Neural Circui … · 4 min read Press Releases NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression June 22, 2026 · 7 min read Press Releases Pheno Therapeutics Granted FDA IND Clearance for Le
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
X-tosis launches custom GPT guide for EOAD and Familial Alzheimer's | X-tosis posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … e. These tools can help streamline the assessment process. Step-by-Step Plan to Apply Findings Start Small: Begin with a pilot program using the predictive model on a limited number of patients. Gather Data: Collect and analyze patient outcomes to see how well the model predicts cognitive decline. Train Staff: Educate healthcare providers on using these models in clinical practice. Expand Gradually: Once proven effective, expand the program to include more patients and integr
Developing VDAC1 Oligomerization Inhibitor for Treating Parkinson’s Disease | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
Welcome back to #RealElevatorPitches! 🚀 Today, Erin Henderson joins Jackson Streeter in the elevator to pitch X-tosis, a company developing therapies targeting mitochondrial dysfunction, a key driver of neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. X-tosis focuses on addressing pathological cell death driven by mitochondrial dysfunction, aiming to preserve cellular function and improve patients' lives. By targeting a shared biological driver across multiple neurodegenerative diseases, the company aims to advance therapies that could bring new hope to pat
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Instagram Instagram Log In Sign Up Close Never miss a post from salvimedia Sign up for Instagram to stay in the loop. Sign up Log in salvimedia • Follow More options salvimedia 101w Only the bold (or crazy) need apply! Join our host, Chris Salvi, and Howard Berman, PhD, as they delve into his inspiring story and the groundbreaking work at Coya Therapeutics, Inc. Howard Berman leads Coya Therapeutics, a Houston biotech innovating Treg-based therapies for neurodegenerative and autoimmune diseases. Discover Howard’s journey and how treatments like COYA 302 are making strides against ALS and Alzhe
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Instagram Instagram Log In Sign Up Close Never miss a post from ufinnovate Sign up for Instagram to stay in the loop. Sign up Log in ufinnovate • Follow More options ufinnovate 2w 🚀 Welcome back to #RealElevatorPitches ! 🚀 Meet Erin Henderson, CEO, President & Co-Founder of X-tosis. Today, Erin joins Jackson Streeter in the elevator to pitch X-tosis, a company developing therapies targeting mitochondrial dysfunction — a core mechanism underlying diseases such as Alzheimer’s, Parkinson’s, and ALS. X-tosis is focused on addressing pathological cell death caused by mitochondrial dysfunction
--> Pipeline | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Drug Development Pipeline XTS Compounds Targeting Broad Therapeutic Applications By inhibiting VDAC oligomerization, XTS compounds have been tested and demonstrated to assist in preventing or treating disease by targeting mitochondrial dysfunction associated with multiple conditions +1 (404) 405-6315 3501 S Main Street, Suite 1 Gainesville, FL 32601 [email protected] bottom of page
--> Technology | X-tosis top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Innovating Mitochondrial Protection Against Neurodegeneration Advancing Disease-Modifying Mitochondrial Medicine X-tosis is developing first-in-class therapeutics that address the upstream biology driving neurodegenerative diseases. Our approach centers on restoring mitochondrial stability and preventing neuronal death—an essential step toward true disease modification in conditions such as Alzheimer’s, Parkinson’s, ALS, and other disorders mar … undamental point of failure, XTS compounds hold potential for broad therapeutic application across diseases characterized by neuronal stress, metabolic imbalance, and inflammation. How XTS001 Works XTS001 targets the root cause of mitochondrial collapse by preventing VDAC1 oligomerization. In neurodegenerative disease: VDAC1 becomes overexpressed VDAC1 oligomerizes, forming toxic pores Mitochondria lose membrane potential and energy production Apoptotic factors leak into
--> X-Tosis | Innovative Alzheimer's Disease Treatments & Drug Development top of page Home Our Team Pipeline Technology News About Us More Use tab to navigate through the menu items. Saving Brain Cells. Changing Lives. X-tosis is a precision-medicine platform company developing first-in-class mitochondrial therapeutics to prevent neuronal loss. Transforming Neurodegenerative Disease Treatment with XTS Compounds X-tosis is advancing first-in-class mitochondrial therapeutics that target the root causes of neurodegeneration. Our VDAC1-modulating compounds are designed to restore mitochondria
X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference January 8, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics GAINESVILLE, Fla., Jan. 08, 2025 (GLOB … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. We provide essential insights, o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy June 23, 2026 | 4 min read Twitter LinkedIn Facebook Email Print GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to … neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) through its Parkinson's Disease Therapeutics Pipeline Program. The funding will support advancement of XTS001, the lead candidate from the company's MitoXTS platform, a patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, toward clinical development for the treatment of Pa … toward clinical development for the treatment of Parkinson's disease (PD). The grant was awarded following a competitive peer-review process evaluating scientific innovation and translational potential. The MJFF Parkinson's Disease Therapeutics Pipeline Program accelerates promising PD therapies from preclinical to clinical stages by supporting innovative approaches that address core disease mechanisms. XTS001 is a brain-penetrant, orally available small molecule designed to … ial function and prevention of apoptosis triggered by cellular stressors. “This grant from MJFF is a major milestone for X-tosis and represents a strong validation of our MitoXTS approach to addressing unmet needs in Parkinson's and other neurodegenerative diseases,” said Yotam Nisemblat, Chief Scientific Officer of X-tosis and Principal Investig